Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
galenabiopharma.com

See what CB Insights has to offer

Business Relationships

7

Service Providers

1

Galena Biopharma Service Providers

1 Service Provider

Galena Biopharma has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Canaccord Genuity Group

Reverse Merger

Investment Bank

Financial Advisor

Service Provider

Canaccord Genuity Group

Associated Rounds

Reverse Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Galena Biopharma Partners & Customers

7 Partners and customers

Galena Biopharma has 7 strategic partners and customers. Galena Biopharma recently partnered with National Cancer Institute on September 9, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

9/30/2015

Partner

National Cancer Institute

United States

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

PORTLAND , Ore. , Sept. 30 , 2015 / satPRnews.com / -- Galena Biopharma , Inc. , a biopharmaceutical company developing and commercializing innovative , targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care , today announced a collaboration with the National Cancer Institute to initiate a new , Phase 2 clinical trial with NeuVax in patients diagnosed with Ductal Carcinoma in Situ .

2

8/5/2015

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/5/2015

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/22/2014

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

1/14/2014

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/30/2015

8/5/2015

8/5/2015

7/22/2014

1/14/2014

Type

Partner

Partner

Partner

Licensor

Licensee

Business Partner

National Cancer Institute

Country

United States

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

Galena Biopharma Collaborates With the National Cancer Institute on a Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Ductal Carcinoma in Situ Patients

PORTLAND , Ore. , Sept. 30 , 2015 / satPRnews.com / -- Galena Biopharma , Inc. , a biopharmaceutical company developing and commercializing innovative , targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care , today announced a collaboration with the National Cancer Institute to initiate a new , Phase 2 clinical trial with NeuVax in patients diagnosed with Ductal Carcinoma in Situ .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.